Molecular Tumor Boards: Uniting Experts to Guide Precision Therapies
Increased genetic sequencing of tumors presents both opportunities and challenges for oncologists who don't specialize in molecular genetics. A molecular tumor board developed under the leadership of Ben Park, M.D., director of precision oncology at Vanderbilt University Medical Center, pools the insights of experts in genetics, precision therapies, bioinformatics, and other disciplines to recommend treatments in tough cases.
"We'll either make recommendations for local trials or prescribe off-label use of therapies. Then the patient can follow up with their local oncologist."
Park and his research team employ genetic testing to identify a tumor's level of sensitivity to drugs. They also utilize liquid biopsies – capturing circulating DNA from cancer cells shed into the bloodstream – to analyze tumors. An international molecular tumor board, established by Park in 2019, has grown to include 17 academic, 12 community and seven international sites.
|